LGVN Longeveron Inc.

Nasdaq longeveron.com


$ 0.63 $ 0.00 (-0.79 %)    

Wednesday, 19-Nov-2025 12:06:23 EST
QQQ $ 597.39 $ 0.33 (0.06 %)
DIA $ 460.33 $ -0.90 (-0.2 %)
SPY $ 661.03 $ 0.28 (0.04 %)
TLT $ 89.18 $ -0.04 (-0.04 %)
GLD $ 374.38 $ -3.39 (-0.9 %)
$ 0.64
$ 0.64
$ 0.62 x 200
$ 0.63 x 1,500
$ 0.63 - $ 0.65
$ 0.62 - $ 2.24
264,188
na
11.76M
$ 0.89
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 08-13-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 02-28-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-14-2024 06-30-2024 10-Q
7 05-14-2024 03-31-2024 10-Q
8 02-27-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-11-2023 06-30-2023 10-Q
11 05-12-2023 03-31-2023 10-Q
12 03-14-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-12-2022 06-30-2022 10-Q
15 05-13-2022 03-31-2022 10-Q
16 03-11-2022 12-31-2021 10-K
17 11-12-2021 09-30-2021 10-Q
18 08-13-2021 06-30-2021 10-Q
19 05-14-2021 03-31-2021 10-Q
20 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 longeveron-to-present-alzheimers-disease-data-at-clinical-trials-on-ad-conference-in-california

Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pe...

 earnings-preview-for-longeveron
Earnings Preview For Longeveron
11/03/2025 21:03:14

 longeveron-entered-into-sales-agreement-for-sale-of-shares-of-class-a-common-stock-for-up-to-107m-from-time-to-time

-SEC Filing

 longeveron-appoints-than-powell-as-interim-chief-executive-officer-effective-immediately-dr-joshua-hare-appointed-as-executive-chairman-of-the-board

MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology c...

 roth-capital-maintains-buy-on-longeveron-lowers-price-target-to-3

Roth Capital analyst Boobalan Pachaiyappan maintains Longeveron (NASDAQ:LGVN) with a Buy and lowers the price target from $1...

 longeveron-q2-eps-033-beats-035-estimate-sales-316000k-miss-414650k-estimate

Longeveron (NASDAQ:LGVN) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.35) by...

 preview-longeverons-earnings
Preview: Longeveron's Earnings
08/12/2025 18:01:38

 longeveron-prices-offering-of-588m-shares-and-147m-accompanying-short-term-warrants-at-085-expected-to-be-5m-potential-additional-gross-proceeds-to-the-company-from-the-short-term-warrants-if-fully-exercised-on-a-cash-basis-will-be-125m

Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage regenerative medicine biotechnology...

 longeveron-licenses-issued-us-patent-for-stem-cell-technology-from-university-of-miami

Longeveron has licensed issued US Patent 12,168,028 B2, entitled "Methods for obtaining cardiomyogenic precursor cells"...

 watching-longeveron-zacks-small-cap-reiterates-955-price-valuation-originally-stated-on-june-24-2025

https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_07082025_LGVN_Sorensen.pdf

 longeveron-announces-fda-approval-of-ind-application-for-stem-cell-therapy-laromestrocel-as-potential-treatment-for-pediatric-dilated-cardiomyopathy

Accepted IND application allows for development program to move directly to a Phase 2 pivotal registration clinical trialPhase ...

 watching-longeveron-zacks-small-cap-research-gives-stock-955-price-valuation

https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_06242025_LGVN_Sorensen.pdf

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION